143 related articles for article (PubMed ID: 34933329)
1. Forced Degradation Study of Zanubrutinib: An LC-PDA and LC-MS Approach.
Gollu G; Gummadi S; Vemuri VD; Nalla S; Mathala N; Allam S
J Chromatogr Sci; 2022 Nov; 60(9):807-816. PubMed ID: 34933329
[TBL] [Abstract][Full Text] [Related]
2. Liquid chromatography/electrospray ionization tandem mass spectrometry study of repaglinide and its forced degradation products.
Purna Chander C; Raju B; Ramesh M; Shankar G; Srinivas R
Rapid Commun Mass Spectrom; 2018 Aug; 32(15):1181-1190. PubMed ID: 29723439
[TBL] [Abstract][Full Text] [Related]
3. LC-PDA-QTof-MS characterization of the stress degradation products of Zanubrutinib: A novel BTK inhibitor.
Bhandi MM; Swain D; Ragampeta S; Mudiam MKR
J Pharm Biomed Anal; 2023 Nov; 236():115714. PubMed ID: 37713985
[TBL] [Abstract][Full Text] [Related]
4. Study of degradation behavior of besifloxacin, characterization of its degradation products by LC-ESI-QTOF-MS and their in silico toxicity prediction.
Salunke N; Kharkar PS; Pandita N
Biomed Chromatogr; 2019 Jun; 33(6):e4489. PubMed ID: 30652327
[TBL] [Abstract][Full Text] [Related]
5. Isolation, Characterization, and Toxicity Study of Stress Degradation Products of Pranlukast Hydrate.
Prajapati KJ; Kothari CS
Chem Res Toxicol; 2022 Jul; 35(7):1206-1219. PubMed ID: 35731702
[TBL] [Abstract][Full Text] [Related]
6. LC-MS-MS Characterization of Forced Degradation Products of Fidarestat, a Novel Aldose Reductase Inhibitor: Development and Validation of a Stability-Indicating RP-HPLC Method.
Talluri MV; Khatoon L; Kalariya PD; Chavan BB; Ragampeta S
J Chromatogr Sci; 2015 Oct; 53(9):1588-96. PubMed ID: 26014964
[TBL] [Abstract][Full Text] [Related]
7. LC/Q-TOF-MS-based structural characterization of enasidenib degradation products and establishment of a stability-indicating assay method: Insights into chemical stability.
Chakkar A; Chaturvedi S; Rajput N; Sengupta P; Sharma N
Rapid Commun Mass Spectrom; 2024 Mar; 38(5):e9696. PubMed ID: 38355880
[TBL] [Abstract][Full Text] [Related]
8. LC and LC-MS/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway.
Mehta L; Naved T; Grover P; Bhardwaj M; Mukherjee D
J Pharm Biomed Anal; 2021 Feb; 194():113768. PubMed ID: 33279300
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product.
Luo Z; Deng Z; Liu Y; Wang G; Yang W; Hou C; Tang M; Yang R; Zhou H
Talanta; 2015 Jul; 139():67-74. PubMed ID: 25882410
[TBL] [Abstract][Full Text] [Related]
10. Method validation and characterization of stress degradation products of azelastine hydrochloride using LC-UV/PDA and LC-Q/TOF-MS studies.
Shekhar S; Bali A
Rapid Commun Mass Spectrom; 2024 Apr; 38(7):e9712. PubMed ID: 38351666
[TBL] [Abstract][Full Text] [Related]
11. Selective Stability Indicating Liquid Chromatographic Method Based on Quality by Design Framework and In Silico Toxicity Assessment for Infigratinib and Its Degradation Products.
Ali AM; Alanazi MM; Attwa MW; Darwish HW
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005198
[TBL] [Abstract][Full Text] [Related]
12. LC and LC-MS/MS studies for identification and characterization of degradation products of d-tubocurarine chloride.
Grover P; Maheshwari S; Nagarajan K; Mehta L; Kumar S; Rastogi C
J Pharm Biomed Anal; 2023 Jan; 223():115119. PubMed ID: 36343537
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC/ESI/QTOF/MS/MS.
Kumar Talluri MVN; Dharavath S; Kalariya PD; Prasanth B; Srinivas R
J Pharm Biomed Anal; 2015 Feb; 105():1-9. PubMed ID: 25527975
[TBL] [Abstract][Full Text] [Related]
14. LC-MS/MS method for the characterization of the forced degradation products of Entecavir.
Ramesh T; Rao PN; Rao RN
J Sep Sci; 2014 Feb; 37(4):368-75. PubMed ID: 24323372
[TBL] [Abstract][Full Text] [Related]
15. Identification, characterisation and in silico ADMET prediction of ozenoxacin and its degradation products using high-performance liquid chromatography-photodiode array and liquid chromatography-quadrupole time-of-flight-tandem mass spectrometry.
Matta A; Sundararajan R
Rapid Commun Mass Spectrom; 2024 Feb; 38(3):e9676. PubMed ID: 38211348
[TBL] [Abstract][Full Text] [Related]
16. Structural identification of degradants of moexipril by LC-MS/MS.
Challa PR; K R; K M V NR
Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28493358
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS studies of ritonavir and its forced degradation products.
Rao RN; Ramachandra B; Vali RM; Raju SS
J Pharm Biomed Anal; 2010 Dec; 53(4):833-42. PubMed ID: 20619992
[TBL] [Abstract][Full Text] [Related]
18. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
Lalitha Devi M; Chandrasekhar KB
J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
[TBL] [Abstract][Full Text] [Related]
19. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method.
Vemuri DK; Gundla R; Konduru N; Mallavarapu R; Katari NK
Biomed Chromatogr; 2022 Jun; 36(6):e5363. PubMed ID: 35292997
[TBL] [Abstract][Full Text] [Related]
20. LC-MS/MS characterization of forced degradation products of zofenopril.
Ramesh T; Nageswara Rao P; Nageswara Rao R
J Pharm Biomed Anal; 2014 Jan; 88():609-16. PubMed ID: 24211724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
